Mankind Pharma Limited — PPTs, 30-07-2026: Investor Presentation

Mankind Pharma delivered strong Q1 FY27 performance, with overall revenue rising 12.9% YoY to 4,031 Cr. EBITDA grew 24.7% to 1,060 Cr, boosting margins by 250 bps to 26.3%. Profit After Tax increased 29.1% to 574 Cr, resulting in a diluted EPS of INR 13.7.

Domestic business (ex-Consumer Healthcare) saw 11.0% growth, led by robust double-digit expansion in chronic therapies like Cardiac (+19.4%) and Anti-diabetes (+12.7%), alongside recovery in acute segments. Exports surged 29.0%. The Consumer Healthcare segment grew 3.9%, with market share gains in key brands.

Strategic focus includes increasing chronic therapy contribution and expanding into specialty and super specialty segments, supported by acquisitions (like BSV) and in-licensing deals. Recent developments include a new product launch in the US and EUGMP certifications for Udaipur and Ambernath facilities.

Management noted that Q1 FY27's improved metrics, driven by disciplined execution, set the stage for sustained long-term growth.